| Clinical data | |
|---|---|
| Trade names | Evra, Ortho Evra |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a602006 |
| Routes of administration |
Transdermal patch |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| Synonyms | Norelgestromine; Levonorgestrel 3-oxime; 17β-Deacetylnorgestimate; 17α-Ethynyl-18-methyl-19-nortestosterone 3-oxime; 17α-Ethynyl-18-methylestr-4-en-17β-ol-3-one 3-oxime |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H29NO2 |
| Molar mass | 327.461 g/mol |
| 3D model (JSmol) | |
|
|
|
|
|
|
|
Norelgestromin, or norelgestromine, is a progestin which is used in the contraceptive patches Evra and Ortho Evra, in combination with the estrogen ethinylestradiol.
Norelgestromin is a progestogen. It is one of the active metabolites of norgestimate. Unlike many related progestins, norelgestromin has negligible androgenic activity.
Norelgestromin, also known as 17α-ethynyl-18-methyl-19-nortestosterone 3-oxime or as 17α-ethynyl-18-methylestr-4-en-17β-ol-3-one 3-oxime, is a synthetic estrane steroid and a derivative of testosterone. It is a racemic mixture of E and Z isomers, which have approximately the same activity. Norelgestromin is more specifically a derivative of norethisterone (17α-ethynyl-19-nortestosterone) and is a member of the gonane (18-methylestrane) subgroup of the 19-nortestosterone family of progestins. It is the C3 oxime derivative of levonorgestrel and the C17β deacetyl derivative of norgestimate and is also known as levonorgestrel 3-oxime and as 17β-deacetylnorgestimate.
Norelgestromin was introduced in 2002.
Norelgestromin is the generic name of the drug and its INN, USAN, and BAN.